Article

Segment 7- Healthcare System Challenges

Panelists agreed that the cost of the new agents discussed to treat melanoma will be a challenge, just as the cost of healthcare as a whole in the United States is a major challenge.

Panelists agreed that the cost of the new agents discussed to treat melanoma will be a challenge, just as the cost of healthcare as a whole in the United States is a major challenge. Figuring out where the waste is in healthcare is difficult. “In order to ensure competition really does have these drugs available at a price that everyone has access to, we’re going to have to use tools like formularies and pathways to highlight where things are equally effective,” said Dr Malin.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
CK Wang, MD, COTA
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Eric Lander, MD
Eric Lander, MD
David Awad, PharmD, BCOP
Andrew Evens, DO, MBA, MSc, deputy director for clinical services and chief physician officer, Rutgers Cancer Institute and Jack & Sheryl Morris Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo